Q 301

Drug Profile

Q 301

Alternative Names: Q301

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Qurient Co
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 22 Aug 2017 Phase-II development is ongoing in USA (Qurient pipeline, August 2017)
  • 01 May 2016 Qurient completes a phase II trial in Atopic dermatitis in USA (NCT02426359)
  • 01 Apr 2015 Phase-II clinical trials in Atopic dermatitis in USA (Topical) (NCT02426359)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top